IJU case reports · 2026
Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer With PSA-Discordant Progression: A Case Report.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Numata Yamato, Kimura Go, Akatsuka Jun, Mikami Hikaru, Obayashi Kotaro, Endo Yuki, Takeda Hayato, Toyama Yuka, Ohashi Ryuji, Kondo Yukihiro
Аннотация
INTRODUCTION: The combination of enzalutamide and radium-223 has demonstrated clinical efficacy in metastatic castration-resistant prostate cancer; however, real-world evidence remains limited, particularly with PSA-discordant progression.
CASE PRESENTATION: A 74-year-old man with high-risk localized prostate cancer was treated with androgen deprivation therapy followed by definitive external beam radiotherapy. Eight months later, the disease progressed radiographically with extensive bone, nodal, and solitary liver metastases, while prostate-specific antigen levels remained persistently low, consistent with prostate-specific antigen-discordant progression. Bone turnover markers and disease activity markers were markedly elevated. Combination therapy with enzalutamide and radium-223 was initiated, and six cycles of radium-223 were completed. Following treatment, skeletal disease activity and bone turnover markers improved markedly. Apart from grade 3 anemia requiring transfusion, no severe adverse events occurred.
CONCLUSION: This case suggests that enzalutamide combined with radium-223 may provide clinical benefit in metastatic castration-resistant prostate cancer with PSA-discordant progression.
CASE PRESENTATION: A 74-year-old man with high-risk localized prostate cancer was treated with androgen deprivation therapy followed by definitive external beam radiotherapy. Eight months later, the disease progressed radiographically with extensive bone, nodal, and solitary liver metastases, while prostate-specific antigen levels remained persistently low, consistent with prostate-specific antigen-discordant progression. Bone turnover markers and disease activity markers were markedly elevated. Combination therapy with enzalutamide and radium-223 was initiated, and six cycles of radium-223 were completed. Following treatment, skeletal disease activity and bone turnover markers improved markedly. Apart from grade 3 anemia requiring transfusion, no severe adverse events occurred.
CONCLUSION: This case suggests that enzalutamide combined with radium-223 may provide clinical benefit in metastatic castration-resistant prostate cancer with PSA-discordant progression.